Innovating Works

MBT

A stranger
VacPath: Novel vaccine vectors to resist pathogen challenge MICROBIOTEC SRL participó en un H2020: H2020-MSCA-ITN-2018 Infectious diseases are a major burden and constant threat to European populations and economies. While barely perceived as a danger not too...
2018-08-30 - 2024-10-31 | financed
VSV-EBOPLUS: SYSTEMS ANALYSIS OF ADULT AND PEDIATRIC RESPONSES TO THE VSV ZEBOV EBOLA VACCINE Sofia ref. 11606... MICROBIOTEC SRL participó en un H2020: H2020-JTI-IMI2-2015-08-single-stage The vesicular stomatitis virus (VSV)-Zaire Ebola vaccine (VSV-ZEBOV) is a recombinant vector-based vaccine in which the VSV envelope glycopr...
2017-06-12 - 2023-03-31 | financed
VSV-EBOVAC: Vaccine safety and immunogenicity signatures of human responses to VSV ZEBOV Sofia ref. 115842 MICROBIOTEC SRL participó en un H2020: H2020-JTI-IMI2-2014-02-single-stage The proposal, VSV-EBOVAC, directly addresses the topic 1 of the IMI2 call on Ebola by supporting the clinical development of a highly promis...
2015-03-19 - 2019-02-28 | financed
CHAARM: Combined Highly Active Anti retroviral Microbicides MICROBIOTEC SRL participó en un FP7: This proposal is for a large scale collaborative project in which we propose both to develop novel microbicides directed against new intrace...
financed
ADITEC: Advanced Immunization Technologies MICROBIOTEC SRL participó en un FP7: Vaccines so far have been developed mostly by following an empiric approach. To prevent and possibly cure unresolved and emerging infectious...
financed
MOTIF: Microbicide Optimization Through Innovative Formulation for Vaginal and Rectal Delivery MICROBIOTEC SRL participó en un FP7: The 40% protection against HIV-1 infection with vaginally-applied tenofovir gel demonstrated in the CAPRISA004 trial, has emphasized develop...
financed
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.